Ozempic 0.25mg start dose: what the evidence actually shows

What did @kirstyrebeccasjourney actually say?

Honestly? Nothing. The transcript attached to this video is song lyrics, not health commentary. The words "we're getting cold," "never gonna cry," and "where did it all go" are lines from a song playing over what appears to be a food diary video, not spoken claims about Ozempic, GLP-1 therapy, or weight loss. There is no medical content to evaluate in the spoken audio.

That matters, because the video metadata tells a different story. The caption reads "WIEIAD Day 6 - Ozempic 0.25mg" and the hashtag list includes #ozempicsideeffects, #glp1forweightloss, #monjaro, and #semiglutide (misspelled, but clearly meaning semaglutide). This is a "What I Eat In A Day" format diary post from someone documenting their GLP-1 journey. The framing carries implicit weight, even when no words are spoken.

So we are fact-checking the context, not the lyrics.

Does the science back this up?

The broader WIEIAD-on-Ozempic genre reflects something real: semaglutide does meaningfully reduce appetite and food intake, and that reduction is documented in clinical trials. Whether any individual's food diary reflects a healthy or sustainable intake is another question entirely.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. The starting dose in that trial, as in clinical practice, is 0.25mg weekly for the first four weeks, which matches what this creator is documenting. That dose is a titration step, not a therapeutic dose. It is not expected to produce significant weight loss on its own.

Appetite suppression at 0.25mg is reported by some patients but is not the primary effect at that stage. A 2022 analysis by Davies et al. in Diabetes Care confirmed that GLP-1 receptor agonists reduce caloric intake partly through slowed gastric emptying and partly through central appetite signalling in the hypothalamus. Neither mechanism is fully active at sub-therapeutic doses.

What did they get wrong (or right)?

There are no spoken claims here to label right or wrong. But the video's implicit framing, a single person documenting low food intake while on Ozempic, carries some risks worth naming.

WIEIAD content on GLP-1 medications has attracted criticism from dietitians and eating disorder specialists. When creators document very low calorie days as desirable outcomes of medication, it can normalise insufficient intake for people who are sensitive to that content. The hashtag #wieiadweightloss makes the intent explicit.

At 0.25mg, the dose shown here, the clinical picture is genuinely early. Patel et al. (2023, Obesity Reviews) noted that adverse events including nausea, vomiting, and reduced appetite are common in the titration phase and should prompt clinical monitoring, not dietary restriction layered on top. If this creator is eating significantly below their needs because of medication-induced nausea at week one, that is not evidence of the medication working. It is a side effect.

To be fair to the creator, they are not telling anyone to do anything. They are just filming their day. That context matters.

What should you actually know?

If you are starting semaglutide at 0.25mg and watching content like this, a few things are worth knowing. First, 0.25mg is a titration dose. Most prescribing guidelines, including those from the MHRA in the UK, treat this phase as a tolerance check, not a weight loss phase. Expecting dramatic results here, or restricting food further to accelerate results, is not supported by the pharmacology.

Second, GLP-1 medications work best alongside adequate protein intake and resistance activity. Wilding et al. (2021) and subsequent STEP trial data showed lean mass loss alongside fat mass loss, which is a genuine concern. Eating very little during the titration phase does not protect muscle. It risks it.

Third, if you are in the UK and accessing Ozempic for weight management, be aware that Ozempic is licensed for type 2 diabetes in the UK. Wegovy (semaglutide 2.4mg) is the licensed weight management product. This creator uses the hashtag #type2diabetes, which may indicate a licensed use, but the overlap in social content between diabetes patients and people using semaglutide off-label for weight loss is something prescribers and platforms should both take seriously.

Finally, compounded semaglutide products are not equivalent to branded Ozempic or Wegovy. If you are accessing semaglutide through any route other than a licensed pharmacy dispensing a branded product, that is a different risk profile and should be discussed with a prescriber.